INDIANAPOLIS, March 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call for the media and investment community to provide a pipeline update for its diabetes business on Monday, June 24, 2013. The call, which is being held in conjunction with the 73rd American Diabetes Association Scientific Sessions, will include updates on Phase III data for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor, and dulaglutide, an investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist. Empagliflozin is in development in partnership with Boehringer Ingelheim.
The conference call will be held from 7 p.m. to 8:30 p.m. US Central Time (CDT). Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at www.lilly.com. The webcast of the conference call will be available for replay through July 24, 2013.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers through medicines and information for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutionsfrom medicines to support programs and moreto make lives better. For more information, visit www.lillydiabetes.com.
(317) 701-4007 Kelley Murphy (media)
(317) 655-6874 Philip Johnson (investors)
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20111111/DE03493LOGO )
SOURCE Eli Lilly and Company